Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205

Trial Profile

Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs MVA-HIV62 (Primary) ; PGA2-JS7 (Primary)
  • Indications HIV infections
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2013 New trial record
    • 24 Jan 2013 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top